This latest edition of the AGA Clinician’s Companion, published online quarterly, summarizes research findings most relevant to clinicians on the risk of inflammatory bowel diseases (IBD) in patients with microscopic colitis, differences in low- vs high-volume split doses for bowel preparation, prevalences of gastroesophageal reflux disease (GERD) and symptoms refractory to proton pump inhibitor (PPI) therapy, and GERD phenotypes.
This quarter’s edition includes summaries of studies into the safety of JAK inhibitors (tofacitinib, upadacitinib, filgotinib, and baricitinib) in patients with IBD, psoriasis, or ankylosing spondylitis, as well as the effects of hormone therapy in patients with IBD.
Other research findings summarized for clinicians include the effects of combination therapy with nucleic acid polymers (NAPs) in patients with chronic HBV infection, outcomes of obeticholic acid treatment in patients with primary biliary cholangitis (PBC), and risk factors for and outcomes of venous thromboembolism in patients with pancreatic cancer.
Companion articles in this issue summarize for clinicians the diagnostic accuracy of contrast endoscopic ultrasound (EUS) in evaluation of pancreatic masses, neuropsychological effects of celiac disease, and a network meta-analysis of therapies for irritable bowel syndrome with constipation (IBS-C).
The AGA Clinician’s Companion summaries cover impactful findings published in the AGA journals Gastroenterology and Clinical Gastroenterology and Hepatology (CGH). An annual subscription provides access to all 4 issues for the current year as well as past issues.